Article
Humanigen, Thermo Fisher strike deal to scale up manufacturing of monoclonal antibody for COVID-19
Rating:
0.0
Views:
56
Likes:
1
Library:
1
In the earliest days of the COVID-19 pandemic, a suite of drugmakers looked to monoclonal antibodies as a possible therapy for the immune system overreaction seen in severe patients. Months later, most of those candidates have had mixed success, but Humanigen is pressing ahead—and it's bringing on partners to help scale for market.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value